Jazz Pharmaceuticals (JAZZ) Now Covered by Leerink Swann

Equities research analysts at Leerink Swann started coverage on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report released on Tuesday. The brokerage set an “outperform” rating and a $180.00 price target on the specialty pharmaceutical company’s stock. Leerink Swann’s price objective suggests a potential upside of 29.56% from the company’s current price.

A number of other brokerages also recently issued reports on JAZZ. FBR & Co initiated coverage on Jazz Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $206.00 target price for the company. Royal Bank of Canada cut their target price on Jazz Pharmaceuticals from $210.00 to $195.00 and set an “outperform” rating for the company in a research note on Wednesday, November 8th. Goldman Sachs Group initiated coverage on Jazz Pharmaceuticals in a research note on Thursday, September 28th. They set a “neutral” rating and a $165.00 target price for the company. UBS Group reissued a “buy” rating and set a $172.00 target price (down from $175.00) on shares of Jazz Pharmaceuticals in a research note on Monday, September 25th. Finally, Zacks Investment Research downgraded Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $181.68.

Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) traded up $1.53 during mid-day trading on Tuesday, hitting $138.93. The stock had a trading volume of 366,900 shares, compared to its average volume of 348,750. The stock has a market cap of $8,330.00, a P/E ratio of 22.89, a price-to-earnings-growth ratio of 0.76 and a beta of 0.97. Jazz Pharmaceuticals has a fifty-two week low of $112.22 and a fifty-two week high of $163.75. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63.

In other Jazz Pharmaceuticals news, SVP Iain Mcgill sold 8,000 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the sale, the senior vice president now owns 28,383 shares in the company, valued at approximately $3,786,859.86. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Patrick G. Enright sold 9,000 shares of the stock in a transaction on Monday, December 11th. The shares were sold at an average price of $139.73, for a total value of $1,257,570.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,552 shares of company stock worth $2,399,643. Insiders own 4.30% of the company’s stock.

A number of large investors have recently made changes to their positions in JAZZ. Dimensional Fund Advisors LP lifted its stake in shares of Jazz Pharmaceuticals by 49.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 229,898 shares of the specialty pharmaceutical company’s stock worth $35,750,000 after purchasing an additional 75,703 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Jazz Pharmaceuticals by 41.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock worth $218,540,000 after purchasing an additional 410,031 shares during the period. Summit Partners Public Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth $10,108,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth $296,000. Finally, Schroder Investment Management Group purchased a new position in shares of Jazz Pharmaceuticals during the 3rd quarter worth $52,571,000. Hedge funds and other institutional investors own 90.73% of the company’s stock.

WARNING: This piece was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://transcriptdaily.com/2018/01/04/jazz-pharmaceuticals-jazz-now-covered-by-leerink-swann.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply